THE EFFECT OF CHEMOKINE CXCL-13 ON THE CLINICAL AND FUNCTIONAL STATUS OF PATIENTS WITH MULTIPLE SCLEROSIS IN REMISSION
- Authors: Sursiakova NV1, Kuklina EM2, Baidina TV1, Nekrasova IV2
-
Affiliations:
- E.A. Vagner’s Perm State Medical University, Perm
- Institute of Ecology and Genetics of Microorganisms, the Ural Branch of the Russian Academy of Science, Perm
- Issue: Vol 19, No 1S (2019)
- Pages: 117-119
- Section: Articles
- URL: https://journals.rcsi.science/MAJ/article/view/19356
- ID: 19356
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N V Sursiakova
E.A. Vagner’s Perm State Medical University, Perm
E M Kuklina
Institute of Ecology and Genetics of Microorganisms, the Ural Branch of the Russian Academy of Science, Perm
T V Baidina
E.A. Vagner’s Perm State Medical University, Perm
I V Nekrasova
Institute of Ecology and Genetics of Microorganisms, the Ural Branch of the Russian Academy of Science, Perm
References
- Disanto G, Morahan J, Barnett M, et al. The evidence for a role of B cells in multiple sclerosis. Neuro¬logy. 2012;78(11):823-832.
- Havenar-Daughton С, Lindqvist М, Heit А, et al. CXCL13 is a biomarker of germinal center activity. Proceedings of the National Academy of Sciences. 2016;113(10):2702-2707.
- Shi G, Zhang Z, Li Q. New Biomarkers in Autoimmune Disease. Journal of Immunology Research. 2017;2017:1-2.
- Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Multiple Sclerosis Journal. 2011;7(7):819-829.
- Edwards KR, Goyal J, Plavina, et al. Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis. PLoS ONE. 2013;8(11):10-13.
- Novakova L, Axelsson M, Khademi M, et al. Cerebrospinal fluid biomarkers as a measure of disease acti¬vity and treatment efficacy in relapsing-remitting multiple sclerosis. J. Neurochem 2017;141:296-304.
Supplementary files
